Corona Remedies Ltd Financials
Company Logo

Corona Remedies Ltd Financial Statement

Corona Remedies Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2025
Revenue363.40
Operating Expense282.66
Net Profit52.15
Net Profit Margin14.35
Earning Per Share8.53
EBIDTA79.13
Effective Tax Rate19.63

Corona Remedies Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual1,196.42
Operating Expenses Annual956.44
Operating Profit Annual245.91
Interest Annual10.60
Depreciation15.39
Net Profit Annual149.05
Tax Annual49.10

Corona Remedies Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning3.16
Cash Flow from Operations190.49
Cash Flow from Investing-83.84
Cash Flow from Financing-106.59
Cash Flow at the End3.22

Corona Remedies Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)20.55
PBIT Margin (%)17.45
PBT Margin (%)15.80
Net PROFIT Margin (%)12.46
Return On Networth / Equity (%)27.45
Return On Networth /Employed (%)29.78
Return On Assets (%)21.30
Total Debt / Equity (X)0.23
Asset Turnover Ratio (%)1.71

Corona Remedies Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual369.88
Total Current Assets Annual338.87
Non Current Assets Annual590.37
Total Shareholders Funds Annual605.73
Total Assets Annual929.24

Corona Remedies Ltd Earning Calls

EPS (INR)

Expected

8.55

Reported

8.55

Surprise

0.00%

Jun 2025

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Corona Remedies Ltd Financials

As of Jan 8, 2026, Corona Remedies Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.

Yes, Corona Remedies Ltd is with a debt-to-equity ratio of 0.14.

In FY 2025 , Corona Remedies Ltd recorded a total revenue of approximately 1,196.42 Cr marking a significant milestone in the company's financial performance.

Corona Remedies Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising annually..

Corona Remedies Ltd's current PE ratio is .

Corona Remedies Ltd's ROCE averaged 30.2% from the FY ending March 2025 to 2025, with a median of 30.2%. It peaked at 30.2% in March 2025, reflecting strong capital efficiency over the period..

Corona Remedies Ltd's latest EBIT is Rs. 208.75 Cr, surpassing the average EBIT of Rs. 208.75 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions